Octapharma’s Acquired Coagulation Factor Deficiency Medication Receives FDA Approval
Balfaxar indicated for restoration of blood coagulation.
Octapharma, a human protein product manufacturer, has announced the FDA approval of Balfaxar, a treatment for acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. According to the company, the medication works to replenish deficient clotting factors due to warfarin therapy, ultimately restoring blood coagulation.
“The FDA approval of Balfaxar® establishes a new therapy for medical providers when their patients need a 4F-PCC product,” said Flemming Nielsen, President, Octapharma USA, in a company press release. "Octapharma is committed to providing patients with lifesaving and life-enhancing therapies for critical care medicine. We are confident Balfaxar® will be a welcomed treatment for physicians who need to quickly restore patients’ coagulation.”
Reference: Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures. Octapharma USA. July 26, 2023. Accessed July 27, 2023. https://www.octapharmausa.com/news/press-release/2023/octapharmas-prothrombin-complex-concentrate-balfaxar-receives-fda-approval-for-warfarin-reversal-in-urgent-surgery-invasive-procedures
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
